Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Notes Payables (2023 - 2025)

Jin Medical International's Notes Payables history spans 3 years, with the latest figure at $18.8 million for Q3 2025.

  • For Q3 2025, Notes Payables rose 66.37% year-over-year to $18.8 million; the TTM value through Sep 2025 reached $18.8 million, up 66.37%, while the annual FY2025 figure was $18.8 million, 66.37% up from the prior year.
  • Notes Payables for Q3 2025 was $18.8 million at Jin Medical International, up from $11.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $18.8 million in Q3 2025 and bottomed at $4.1 million in Q3 2023.
  • The 3-year median for Notes Payables is $11.3 million (2024), against an average of $11.4 million.
  • The largest annual shift saw Notes Payables soared 175.28% in 2024 before it skyrocketed 66.37% in 2025.
  • A 3-year view of Notes Payables shows it stood at $4.1 million in 2023, then soared by 175.28% to $11.3 million in 2024, then surged by 66.37% to $18.8 million in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Notes Payables are $18.8 million (Q3 2025), $11.3 million (Q3 2024), and $4.1 million (Q3 2023).